Keywords: novartis, diovan, effective, norvasc, hypertensive, patients, high
Novartis' Diovan as effective as Norvasc in hypertensive patients with high
Article | 28 June 2004
Results have been published in The Lancet from the eagerly-awaited VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial, which compared Novartis' ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
